Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MiniMed

This article was originally published in The Gray Sheet

Executive Summary

Nets $141.2 mil. from a secondary offering of approximately 2.6 mil. shares of common stock at $68.375 each, including overallotment shares. The infusion system maker had planned an offering of 2.3 mil. shares, including 300,000 shares offered by a selling shareholder (1"The Gray Sheet" July 5, p. 26). Overallotment shares included 172,500 purchased from the company and 172,500 shares from a selling stockholder. The deal was underwritten by Warburg Dillon Read LLC. Co-managers of the offering included Hambrecht & Quist LLC, ING Baring Furman Selz LLC and Volpe Brown Whelan & Company

You may also be interested in...



MiniMed Glucose Monitor Approval Sweet As Stock Gains 30% In June

FDA approval of MiniMed's continuous glucose monitoring system (CGMS) June 16 helped sweeten the company's stock price during the month.

Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel